Evidence now suggests eating soy foods in puberty protects against breast cancerApril 09, 2008But to be useful, the way soy works needs to be better understood, says researcher Washington, D.C. - Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today. The challenge now, she says, is for scientists to understand precisely why soy appears to provide a shield against the most common cancer in women. "Timing seems to be vitally important in use of this bioactive food, and if we can figure out why that is so, then we may be able to help prevent breast cancer in the widest sense possible," says the researcher, Leena Hilakivi-Clarke, Ph.D., a professor of oncology at the Lombardi Comprehensive Cancer Center at Georgetown.
Although there are a number of tantalizing theories to explain the connection, "at the present time no convincing explanation can be offered as to why the breast cancer-risk reducing effect of genistein might be strongest during childhood and early adolescence," she says. Hilakivi-Clarke is a senior author of a review article published in the journal that sums up the state of knowledge concerning the role of early life genistein exposures in modifying breast cancer risk. She has long studied the link between soy use and breast cancer, as have her three co-authors, all Finnish researchers. There have only been three human studies that tracked soy use during puberty and later breast cancer development, and two of them focused on Asian females, who eat soy in their traditional diet. But these studies suggest soy offers a very strong protective effect - a 50 percent or more reduction in the risk of breast cancer - when soy is eaten during childhood and adolescence. The strongest evidence for genistein's protective effect comes from studies in mice and rats, Hilakivi-Clarke says. For example, numerous studies in rats show that the data regarding prepubertal exposure to genistein are very consistent in showing a reduction in mammary cancer risk, she says. Exposure to soy in fetal development or in adult life does not have the same protective effect. Further examination of experimental versus control rats demonstrated that use of genistein in puberty cut the number of so-called "terminal end buds" in the breast. These are the structures that lead to growth of the mammary epithelium, which are the cells lining milk ducts, etc., and it is in these epithelial cells that breast cancer originates. But Hilakivi-Clarke says it is not clear if a mere reduction in the number of these structures could reduce cancer risk, or why. Other studies suggest that genistein controls expression of genes in terminal end buds that regulate cell growth, repair and death. For example, the chemical could be controlling the ability of stem cells, found on these buds, to reproduce themselves or to differentiate into more specialized cells. "There is evidence that suggests that the more stem cells there are on these structures, the greater the risk of breast cancer development," she says. This evidence supports the theory that breast cancer arises from stem cells that have lost growth control. Other associated research has found that the genes that genistein appears to activate in developing mammary glands are well known --- BRCA1, p53, and PTEN tumor suppressors, Hilakivi-Clarke says. These genes repair genetic damage and control cell survival and death, and they may also help control stem cell reproduction, she says, and genistein apparently "up-regulates" these genes, boosting production of their beneficial proteins. What is perhaps most intriguing, she says, is that the same process that protects the breast from excess growth during pregnancy seems to be at work during puberty. "In pregnancy, BRCA1 is also up-regulated, perhaps in order to control the fate of stem cells, allowing them to make more cells for milk production, for example, but not more of themselves." So Hilakivi-Clarke favors the notion that genistein is acting as a breast cancer protective just as an early first pregnancy in women is known to protect against later development of the cancer: "If malignancies occur in breast stem cells, then it is better that many of these cells are differentiated earlier rather than later. Pregnancy hormones do that, so the shorter time there is between puberty and pregnancy, the greater that protection may be," she says. "Genistein may also help control the fate of stem cells in the same way." "We think this is the mechanism by which genistein works, but we really don't know and we need to find out," Hilakivi-Clarke says. "The findings will matter." Georgetown University Medical Center | |||||||||||||||||||||
|
Related Breast Cancer Current Events and Breast Cancer News Articles Clue to genetic cause of fatal birth defect A novel enzyme may play a major role in anencephaly, offering hope for a genetic test or even therapy for the rare fatal birth defect in which the brain fails to develop, according to a study from researchers at the University of Illinois at Chicago College of Medicine. Bisphenol A linked to chemotherapy resistance Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists. Tamoxifen chemoprevention tied to early detection of breast cancer The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute. Herbal Menopause Therapy a Good Fit for Breast Cancer Patients? When it comes to understanding the effectiveness and safety of using herbal therapies with other drugs, much is unknown. Now, a University of Missouri researcher will study how black cohosh - an herbal supplement often used to relieve hot flashes in menopausal women - interacts with tamoxifen, a common drug used to treat breast cancer. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). Study looks at psychological impact of gene test for breast cancer Personal beliefs about inconclusive DNA testing for hereditary breast cancer are associated with cancer-related worry, and such beliefs are an especially strong predictor of whether women had been able to leave the period of DNA-testing behind. Second lumpectomy for breast cancer reduces survival rates A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. MRI spots DCIS in mice A new magnetic resonance imaging procedure can detect very early breast cancer in mice, including ductal carcinoma in situ (DCIS), a precursor to invasive cancer. Some of the tumors detected were less than 300 microns in diameter, the smallest cancers ever detected by MRI. Birth size is a marker of susceptibility to breast cancer later in life Birth size, and in particular birth length, correlates with subsequent risk of breast cancer in adulthood, according to a new study published in PLoS Medicine by researchers at the London School of Hygiene and Tropical Medicine. Social class dictates cancer risk Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||